05:26 PM EDT, 08/14/2024 (MT Newswires) -- ArriVent BioPharma ( AVBP ) reported a Q2 net loss late Wednesday of $0.65 per diluted share, narrowing from a loss of $10.79 a year earlier.

Four analysts polled by Capital IQ expected a loss of $0.61 per share.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, the clinical-stage biopharmaceutical company said it had $298.7 million in cash and cash equivalents that could fund operations into 2026.